Switzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones

By Reuters News


Overview

  • Switzerland specialty pharma firm's H1 revenue rose 101% yr/yr, driven by AGAMREE sales and milestones

  • Product sales for H1 climbed 48% yr/yr, reflecting growth in launched European markets

  • Net loss for H1 narrowed to CHF 21.5 mln from CHF 38.8 mln a year earlier


Outlook

  • Santhera maintains 2026 revenue guidance at CHF 80–90 mln

  • Company expects product sales to grow by more than 50% in 2026

  • Cash seen broadly stable through year-end, with decline expected in H1 2027 before recovery


Result Drivers

  • EU MARKET EXPANSION - Pricing and reimbursement agreements in Spain and Italy enabled AGAMREE commercial launches in four of five major EU markets

  • APAC LICENSING DEAL - Exclusive Nxera agreement for Japan, South Korea, Australia and New Zealand drove milestone and royalty income


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Loss Per Share

CHF 1.50

H1 Net Loss

CHF 21.5 mln

H1 Operating Income

-CHF 6.6 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Santhera Pharmaceuticals Holding AG is CHF27.50, about 82.4% above its September 29 closing price of CHF15.08


Reuters Recommended Reads

  • Sept 29 - Swiss regulator concludes action against Julius Baer, shares surge


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.